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Recently increased availability of anti-retroviral
therapy (ART) has mitigated HIV-1/AIDS prog-
noses especially in resource poor settings. The
emergence of ART resistance-associated muta-
tions from non-suppressive ART has been impli-
cated as a major cause of ART failure. Reverse
transcriptase inhibitor (RTI)-resistancemutations
among 12 non-subtype B HIV-1-infected children
with treatment failure were evaluated by genoty-
pically analyzing HIV-1 strains isolated from
plasma obtained between 2001 and 2004. A
region of pol-RT gene was amplified and at
least five clones per sample were analyzed.
Phylogenetic analysis revealed HIV-1 subtype
A1 (n¼ 7), subtype C (n¼ 1), subtype D (n¼3),
and CRF02_AG (n¼ 1). Before treatment, 4 of
12 (33.3%) children had primary RTI-resistance
mutations, K103N (n¼ 3, ages 5–7 years) and
Y181C (n¼1, age 1 year). In one child, K103N
was found as a minor population (1/5 clones)
before treatment and became major (7/7 clones)
8 months after RTI treatment. In 7 of 12 children,
M184V appeared with one thymidine-analogue-
associated mutation (TAM) as the first mutation,
while the remaining 5 children had only TAMs
appearingeither individually (n¼2), or asTAMs1
(M41L, L210W, and T215Y) and 2 (D67N, K70R,
andK219Q/E/R) appearing together (n¼ 3). These
results suggest that ‘‘vertically transmitted’’
primary RTI-resistance mutations, K103N and
Y181C, can persist over the years even in the
absence of drug pressure and impact RTI treat-
ment negatively, and that appearing patterns
of RTI-resistance mutations among non-subtype
B HIV-1-infected children could possibly be
different from those reported in subtype
B-infected children. J. Med. Virol. 79:865–
872, 2007. ! 2007 Wiley-Liss, Inc.
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INTRODUCTION
The emergence of anti-retroviral drug (ARV)-resis-
tance mutations is a major cause of anti-retroviral
treatment (ART) failure [D’Aquila et al., 1995; Lorenzi
et al., 1999; Zolopa et al., 1999]. These drug-resistant
HIV-1 strains can be transmitted through vertical,
sexual, and parenteral routes [Erice et al., 1993; Conlon
et al., 1994; Boden et al., 1999; Little et al., 1999;
Brenner et al., 2000; Pillay et al., 2000; Salomon et al.,
2000; Duwe et al., 2001]. Vertically transmitted multi-
drug resistant HIV-1 strain has been shown to persist
for 9 months in an infant after postnatal therapy
[Johnson et al., 2001]. Similarly, K103N-containing
HIV-1 variants acquired after the administration of
single dose-nevirapine, a non-nucleoside reverse-
transcriptase inhibitor (NNRTI), have been reported
to persist for more than 1 year in some women and
infants after vertical transmission [Flys et al.,
2005]. However, long-term persistence of vertically
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transmittedARV-resistancemutations in the absence of
drug pressure among infants and children is yet to be
demonstrated.
Recently, the importance of ARV-resistant strains
detected asminor populations has been reported. Minor
drug-resistant HIV-1 populations have been detected
both in the early phase of treatment failure [Coffin,
1995] and during successful structured treatment
interruption [Metzner et al., 2003]. Minor drug-resis-
tant populations undetectable by conventional assays
can eventually overgrow and affect the clinical course
[Dykes et al., 2004; Lecossier et al., 2005]. These minor
drug-resistant populations have also been found to
persist longer than expected previously in untreated
patients, a favorable condition for wild-type virus to
overgrow, which also indicates the risk of resistance
transmission even from minor strains [Charpentier
et al., 2004].
In patients experiencing treatment failure with
nucleoside reverse-transcriptase inhibitors (NRTI),
such as lamivudine plus either zidovudine or stavudine,
theM184Vmutationhasbeen reported toalwaysappear
first, eventually followed by cumulative acquisition
of thymidine-analogue-associated mutations (TAMs) if
treatment with non-suppressive regimen is continued
[Johnson et al., 2005]. Extensive studies on ARV-
resistance suggest that HIV-1 may develop TAMs by
either one of two distinct pathways; TAM 1 (M41L,
L210W, and T215Y) or TAM 2 (D67N, K70R, and
K219Q/E/N/R) [Flandre et al., 2003; Cozzi-Lepri et al.,
2005]. However, most of these studies have focused on
HIV-1 subtype B, which accounts for only 12% of the
global HIV/AIDS pandemic, and data on non-subtype B
HIV-1 is still limited. Furthermore, several differences
in the development of ARV-resistance between subtype
B and non-subtype B HIV-1 have been suggested
[Apetrei et al., 1998; Quinones-Mateu et al., 1998;
Pieniazek et al., 2000]. Most ARV-resistance studies
have focused on adult populations [Yerly et al., 1998; de
Ronde et al., 2001; Dykes et al., 2001; Brenner et al.,
2002;Wainberg, 2003].However, thesefindingsmaynot
be applicable directly to children, since several factors
influencing selection of ARV-resistance such as phar-
macokinetic properties; drug safety, tolerance, and
antiviral activity of combination therapy, are usually
different in the children [Kline et al., 1996].
Theaimof this studywas to investigate thepatterns of
emergence and the variable stability of ARV-resistance-
associated mutations among non-subtype B HIV-1-
vertically-infected children who developed eventually
clinical failure with subsequent ART.
METHODS
Study Population
The subjects in this study resided in children’s home
in Nairobi, which housed 95 HIV-1-infected children.
These children were born to HIV-1-infected mothers
who either died of, or were too debilitated by HIV/AIDS
hence could not offer basic care to the children. Of 95
children 55 were on ART as of August 2004. The
duration of ART varied among children (mean:
23.3 months, range: 5–46 months). Of 55 children on
ART 12 (8 males and 4 females, mean age: 7.4 years)
experienced treatment failure, characterized by an
initial decrease in plasma viral load (to undetectable
level in one child) after treatment initiation and
subsequent increase in the viral load as treatment
continued. Seven of the 12 children received single
ART regimen only during the study period: 5 received
zidovudine/lamivudine/nevirapine, 1 zidovudine/did-
anosine/efavirenz, and 1 zidovudine/lamivudine/efavir-
enz (Table I). On the other hand, the remaining five
children received multiple ART regimen during the
study period: two received zidovudine/lamivudine/
efavirenz followed by zidovudine/didanosine/efavirenz,
two zidovudine/lamivudine/nevirapine followed by
didanosine/lamivudine/efavirenz, and one didanosine/
lamivudine/abacavir followed by zidovudine/didano-
sine/efavirenz and later didanosine/stavudine/efavirenz
(Table I). These 12 childrenwere admitted into thehome
by their first birthday and their HIV-1 status was
confirmed serologically at 18 months of age. None of
these children had history of previous exposure to any
ARV.
This study was approved by the Kenya Medical
Research Institute’s National Ethical Review Commit-
tee on behalf of the Kenyan Government and conducted
according to the national and international regulations
governing the use of human subjects in biomedical
research. The study was conducted within the continu-
ing anti-retroviral, medical and healthcare programs of
the institution without additional demand for blood
samples solely for research purposes.
CD4þ Cell Counts and Plasma Viral Loads
CD4þ T cell counts of peripheral blood were deter-
mined using the FACSCOUNT (Becton-Dickinson,
Beiersdorf, Germany) and plasma HIV-1 RNA loads
using theAmplicorHIV-1Monitor kit version1.5 (Roche
Diagnostics, Alameda, CA) with detection limit of
400 copies/ml according to the manufacturer’s instruc-
tions.
Extraction and Amplification of
Plasma HIV-1 Viral RNA
HIV-1RNAwas extracted from100 ml of plasma using
SMITEST EX-R and D (Sumitomo Metal Industries,
Tokyo, Japan) according to the manufacturer’s instruc-
tions. A region of the pol-RT gene (corresponding to nt
2480–3180 of HIV-1HXB2) was amplified by both one-
step RT-PCR (Invitrogen, Carlsbad, CA) and nested
PCR with primer pairs, RT18 (50-GGAAACCAAAAAT-
GATAGGGGGAATTGGAGG-30) and KS104 (50-TGAC-
TTGCCCAATTTAGTTTTCCCACTAA-30) in the first
round, and KS101 (5-GTAGGACCTACACCTGTTC-
AACATAATTGGAAG-3) and KS102 (50-CCCAT-
CCAAAGAAATGGAGGAGGTTCTTTCTGATG-30) in
the second round [Ndembi et al., 2004; Songok et al.,
J. Med. Virol. DOI 10.1002/jmv
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Drug Resistance in Non-B HIV-1 Infected Children 867
2004]. Amplification was done with 1 cycle of 958C for
10 min and 35 cycles of 958C for 30 sec, 558C for 30 sec,
and 728C for 1 min, with a final extension of 728C for
10 min. PCR amplification was confirmed by ethidium
bromide staining of samples electrophoresed on an
agarose gel.
Cloning, Sequencing, and Subtyping
The amplified products were cloned using the TOPO
TA Cloning kit (Invitrogen) and sequenced as described
previously [Ndembi et al., 2004; Songok et al., 2004].
The sample nucleotide sequences were aligned with
HIV-1 subtype reference sequences from the Los
Alamos database by CLUSTALW (version 1.81) with
minor manual adjustments. Phylogenetic trees were
constructed and visualized as described previously
[Ndembi et al., 2004; Songok et al., 2004]. To improve
the accuracy of HIV-1 subtyping, we used the genotyp-
ing tool (http://www.ncbi.nih.gov/projects/genotyping/
formpage.cgi), and the REGA subtyping tool (http://
dbpartners.stanford.edu/RegaSubtyping/) as needed.
RTI Resistance-Associated Mutations
The RT nucleotide sequences (697 bps) were trans-
lated into the corresponding 232 amino acids and
analyzed for previously reported drug resistance-asso-
ciatedmutations in subtypeBstrainsusing theStanford
university HIVdb sequence analysis program. For each
sample, at least five cloneswere obtained and genotyped
to detect the presence of minor populations.
RESULTS
Generalcharacteristics, treatmenthistory,demographic,
immunological, and virological data of the 12 HIV-1-
infected children studied are summarized in Table I.
HIV-1 Subtypes
All children were infected with non-subtype B HIV-1:
subtype A1 (n¼7), subtype C (n¼ 1), subtype D (n¼3),




Of the 12 children, 4 (33.3%) harbored NNRTI-
resistance mutations before treatment. Three children,
NYU44 (age, 7 years), NYU69 (5 years), and NYU70
(6 years), had K103N while NYU90 (1 year) had Y181C
detected before treatment (Table I). All the mutations
but one (one of seven clones in NYU69) were detected
as full clones (Table IV). K103N detected in three
children persisted, while Y181C detected in one child
disappeared during treatment.
Emerging Pattern of NRTI
Resistance-Associated Mutations
The patterns of NRTI-resistance mutations are
summarized in Table II. M184V appeared as the first
















































































































































































































































































































































































































































































































































































































































868 Lwembe et al.
primary NRTI-resistance mutation in 3 of 12 children
(NYU69, NYU90, and NYU83), (later followed by the
acquisition of one TAM in NYU83), while M184V
appeared as first primary NRTI-resistance mutation
with one TAM in three children (NYU36, NYU70,
and NYU85) who received zidovudine/lamivudine,
zidovudine/didanosine, or lamivudine/didanosine. The
remaining five children (NYU30, NYU33, NYU38,
NYU44, and NYU62) had a mixture of TAMs appearing
as first mutations. Three of them (NYU44, NYU62, and
NYU38) had both TAM 1 (M41L, L210W, and T215Y)
and TAM 2 (D67N, K70R, and K219Q) profiles detected
together. M184V appeared as the first primary NRTI-
resistance mutation together with V75M in child
NYU79. NYU33 developed K219Q only, a ‘‘secondary’’
NRTI-resistance mutation.
Emerging Pattern of NNRTI
Resistance-Associated Mutations
In four of the five children who received nevirapine
(NYU69, NYU70, NYU85, NYU90) K103N appeared as
the first primary NNRTI-resistance mutation, while in
one (NYU62) G190A appeared as the first mutation
(Table III). In two of the five children who received
efavirenz (NYU44 andNYU 83) K103N appeared as the
first NNRTI-resistance mutation, while in two children
(NYU30 and NYU33) L100I and K101Q, respectively,
appeared as the first NNRTI-resistance mutation. One
child (NYU36) who received didanosine/lamivudine/
abacavir with subsequent change to an efavirenz-
containing regimen developed I178M as the first
NNRTI-resistance mutation, which was replaced later
by appearance of G190A.
One child (NYU79) developed K101E and G190A as
first NNRTI-resistance mutations with nevirapine
therapy and developed additionally Y181C when ART
was changed to efavirenz-containing regimen during
the study period.
In the remaining one child (NYU38) no known
NNRTI-resistance mutation was detected despite
receiving nevirapine—and later efavirenz-containing
regimen (Table III).
Growth of Minor Mutant Virus
Population into Major One
Five of 12 children had RTI-resistance mutations
detected as minor virus populations, which subse-
quently grew into full clones (Table IV). In the remain-
ing seven children no RTI-resistant mutation was
detected as a minor population (data not shown).
RTI-resistance mutations, such as T215F in child
NYU36, T215F in NYU44, D67N/K70R/T215F in
NYU62, and K101Q/K219Q in NYU33, appeared as
minor populations after initiation of treatment, which
overgrew subsequently to major populations.
In one child (NYU69), K103N was found as a minor
population (1/5 clones) before initiationof treatment and
became major population (7/7 clones) 8 months after
treatment.
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DISCUSSION
In the current study, NNRTI resistance-associated
primary mutations, K103N and Y181C, were found
before ART in four (33.3%) of 12 HIV-1-vertically-
infected Kenyan children with subsequent ART failure.
Three children aged 5–7 years already had K103N
mutation, while one child aged 1 year already had
Y181C by the time ART was started. These children
had no history of previous exposure to any ART or blood
transfusion, suggesting that these drug-resistance
mutations were transmitted vertically from their
mothers. However, ART history of these children’s
mothers could not be confirmed, and the use of
nevirapine to reduce transmission ofHIV-1 frommother
to child had not been started by the year 2002 in Kenya
[NASCOP, 2002].
This is the first report on the long-term persistence
of NNRTI-resistance mutation for upto 7 years in
vertically HIV-1-infected children albeit in the absence
of ART. The K103Nmutation has been reported to have
little impact on the replicative capacity of HIV-1,
allowing K103N variants to persist as dominant species
at the expense of the wild strains [Brenner et al., 2002].
Thus, these current findings emphasize the need for
drug-resistance testing among HIV-1-infected children
prior to starting any NNRTI-containing regimen to
avoid earlier treatment failure.
The selection of some ARV-resistance mutations
among minor HIV-1 populations after ART initiation
has been reported previously [Coffin, 1995; Metzner
et al., 2003; Charpentier et al., 2004; Dykes et al., 2004;
Lecossier et al., 2005]. In this study, RTI-resistance
mutations detected infive children asminor populations
after ART initiation subsequently grew into major
populations, resulting in ART failure. In addition, it is
noted that a primary NNRTI-resistance mutation,
K103N, was found in one of five HIV-1 clones from a
drug-naı¨veKenyan child (NYU69), and thisminor drug-
resistant virus became dominant (seven of seven clones)
after 8-months ART, resulting in treatment failure.
Thesefindings indicate thatminorARV-resistantHIV-1
variants existing before therapy can also be an impor-
tant cause of treatment failure, as suggested previously
[Dykes et al., 2004; Lecossier et al., 2005; Johnson et al.,
2006]. Standard genotyping methods can only detect
more than 25% of the virus variants [Gunthard et al.,
1998]. Therefore, in order to pick minor variant popula-
tions and pre-empt treatment failure, more sensitive
detection methods for minor HIV-1 populations would
be required [Edelstein et al., 1998;Gunthardet al., 1998;
Grant et al., 2002; Schuurman et al., 2002; Malet et al.,
2003; Shi et al., 2004; Palmer et al., 2005].
Results from this study suggest the possible existence
of two different patterns of emergence or acquisition of
the TAMs among children who receive thymidine-
analogues such as zidovudine, lamivudine, and/or stavu-
dine. Seven of the 12 children had an initial development
of M184V mutation, followed by the cumulative acquisi-
tion of TAMs, consistent with previous studies of subtype






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































870 Lwembe et al.
BHIV-1 [Johnsonetal., 2005],whichreported thatTAMs
always develop by either one of two distinct pathways,
TAM1 (M41L, L210W, and T215Y) or TAM 2 (D67N,
K70R, andK219Q/E/R), under the pressure of thymidine
analogue-containing ARVs. The remaining five children,
however, developed TAMs only without the initial
appearance of M184V mutation. Additionally, three of
these children developed both TAMs 1 and 2 members
concurrently, discordant with previous reports [Flandre
et al., 2003; Cozzi-Lepri et al., 2005]. One child (NYU33)
developed K219Q and K101Q mutations only, after 2-
year treatment with zidovudine, didanosine, and efavir-
enz. These two mutations have been previously grouped
among the secondary RTI-resistance-associated muta-
tions, unable to cause drug-resistance in the absence of
other primary RTI-resistance-associated mutations
such as K70R or T215F [Garcia-Lerma, 2005]. These
findings therefore suggest the possible existence of
different pathways for development of RTI-resistance in
non-subtype B HIV-1-infected children, different from
those reported in subtype B-infected individuals, and
that secondary RTI-resistance-associated mutations
namely K219Q and K101Q could independently cause
ART resistance among non-subtype B HIV-1-infected
children. Further studies are however needed in order to
confirm these findings.
The K103N mutation has been reported as the most
commonly selected NNRTI-resistance-associated muta-
tion, usually appearing first [Johnson et al., 2005]. The
results fromthe childrenwho receivednevirapine in this
study agree with this observation. However, the chil-
dren who received efavirenz developed a variety of
NNRTI-resistance-associatedmutations, suchasL100I,
K101Q, I178M, and G190A. This is the first report to
show the possibility of the K101Q and I178M to appear
as the first NNRTI-resistance mutations with efavirenz
therapy. L100I, Y181C, and G190A have already been
described [Johnson et al., 2005]. In addition, one child
(NYU38) who received nevirapine and later efavirenz
containing regimendidnothaveanyNNRTI-resistance-
associated mutation despite experiencing treatment
failure, suggesting a possible difference in the initial
selection of NNRTI-resistant mutations between non-
subtype B and subtype B HIV-1-Infected children.
However, considering recent reports on the association
between a homozygous variant of multidrug-resistance
transporter C3435T and good immune recovery [Saitoh
et al., 2005], and the correlation of homozygousCYP2B6
*6 with plasma efavirenz concentrations in HIV-1-
infected individuals treated with efavirenz-containing
regimen [Tsuchiya et al., 2004], further pharmacoge-
netic studies would also be needed to elucidate these
phenomenon.
In conclusion, this study suggests a possible long-term
persistence of ‘‘vertically transmitted’’ NNRTI-resis-
tance mutations in the absence of drug pressure, that
minor populations of RTI-resistant HIV-1 mutants may
impact negatively on the outcome ofART, and that there
is a possible difference in the pattern of appearance
and profile of RTI-resistance mutations between non-
subtype B and subtype B HIV-1-infected children.
Further studies with large population size are needed
to confirm these findings.
SEQUENCE DATA
GenBank accession numbers of the sequences
reported in this study are DQ679541 to DQ679753 for
Pol-RT.
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